• Prostaglandin E2 (PGE2): Receptor Selectivity and Research U

  2026-06-16

  Prostaglandin E2 (PGE2) is a lipid-derived autacoid with potent, selective action on EP GPCR subtypes, widely applied in inflammation research and gastrointestinal mucosal protection. Quantitative receptor binding and clinical benchmarks confirm its centrality in immune regulation studies.

• Bufuralol Hydrochloride in Precision Pharmacokinetics: A New

  2026-06-15

  Explore Bufuralol hydrochloride as a non-selective β-adrenergic receptor antagonist in the context of precision pharmacokinetics. This article uniquely connects advanced organoid technologies with practical assay design for cardiovascular pharmacology research.

• Methicillin Sodium Salt: Mechanistic Insights and Advanced A

  2026-06-15

  Explore the molecular action of Methicillin sodium salt in bacterial cell wall synthesis inhibition, with advanced guidance for designing robust Staphylococcus aureus infection research. This article provides unique mechanistic depth and protocol clarity beyond existing resources.

• Applied Cancer Research with YM-155 Hydrochloride: Survivin

  2026-06-14

  YM-155 hydrochloride from APExBIO enables precise, nanomolar-targeted survivin inhibition for advanced cancer research workflows. This guide details actionable protocols, troubleshooting insights, and translational applications—empowering researchers to maximize reproducibility and impact in apoptosis and tumor regression studies.

• Tofacitinib (CP-690550): Mechanistic Insights for RA Macroph

  2026-06-13

  Explore how Tofacitinib (CP-690550) uniquely reprograms rheumatoid arthritis macrophages by targeting JAK-STAT and mitochondrial pathways. This in-depth analysis reveals new mechanistic insights and assay considerations beyond standard immune modulation protocols.

• Ceftolozane Sulfate: Precision PK/PD for Resistant P. aerugi

  2026-06-12

  Explore the nuanced pharmacokinetic and pharmacodynamic principles underpinning Ceftolozane sulfate’s bactericidal activity against Pseudomonas aeruginosa. This in-depth article reveals how advanced dosing and assay strategies elevate research and clinical outcomes.

• Cefodizime: Advanced Antimicrobial Profiling and Resistance

  2026-06-12

  Explore Cefodizime, a third-generation cephalosporin antibiotic, through a deeper scientific lens—unpacking resistance mechanisms, immunomodulatory effects, and evidence-based assay strategies. This article uniquely informs research decisions with advanced analysis and practical guidance.

• Hyaluronic Acid Sodium Salt in siRNA Delivery and ECM Modeli

  2026-06-11

  Hyaluronic acid sodium salt stands out as a multifunctional biopolymer—both a sophisticated carrier for targeted siRNA therapeutics and an authentic extracellular matrix (ECM) component for cell-based assays. Leveraging its unique viscoelastic and signaling properties, researchers can design reproducible workflows for immune modulation and tissue repair studies.

• S63845: Strategic Activation of Mitochondrial Apoptosis in C

  2026-06-11

  This thought-leadership article examines the mechanistic and translational value of the S63845 MCL1 inhibitor, contextualizing its precision targeting of the mitochondrial apoptotic pathway within the evolving landscape of hematological cancer research. By integrating mechanistic insights, recent peer-reviewed findings, and strategic experimental guidance, we provide a roadmap for translational researchers seeking to maximize the impact and reproducibility of apoptosis modulation in disease models. The article uniquely bridges microbial evasion of apoptosis with targeted pathway activation, positioning S63845 as a next-generation tool for dissecting and therapeutically manipulating cell death in malignancies.

• Selective Spectrophotometric Analysis of β-Lactam Antibiotic

  2026-06-10

  This paper introduces two rapid, selective spectrophotometric methods for quantifying phenolic β-lactam antibiotics in pure and combined pharmaceutical forms. By enabling reliable detection even in the presence of structurally related penicillins like dicloxacillin, the study provides a valuable analytical advance for antibiotic research and quality control protocols.

• Cefiderocol In Vitro Efficacy Against Resistant Gram-Negativ

  2026-06-10

  This study provides a comprehensive in vitro assessment of cefiderocol’s activity against European Pseudomonas aeruginosa and Acinetobacter species, including isolates with resistance to meropenem and recent β-lactam/β-lactamase inhibitor combinations. The findings highlight cefiderocol’s superior efficacy and inform experimental design for research on Gram-negative resistance.

• Molecular Tools Boost A40926 Antibiotic Yields in Nonomuraea

  2026-06-09

  Yushchuk et al. developed and validated new genetic tools to improve production of the glycopeptide antibiotic A40926 in Nonomuraea gerenzanensis. By identifying effective promoters and overexpressing pathway-specific regulatory genes, they achieved significant increases in antibiotic yields, providing a reproducible strategy for enhancing biosynthesis of clinically relevant glycopeptides.

• Methicillin Sodium Salt: Reliable MSSA Assays for Modern Lab

  2026-06-09

  This article demonstrates how Methicillin sodium salt (SKU C3238) streamlines Staphylococcus aureus infection research by ensuring reproducibility and sensitivity in bacterial cell wall synthesis inhibition assays. Scenario-driven Q&A blocks address real laboratory challenges, guiding scientists in protocol optimization and vendor selection for translational MSSA/MRSA models.

• Ziprasidone Augmentation in Anxious Depression: Study Analys

  2026-06-08

  A recent post-hoc analysis investigated whether ziprasidone augmentation of escitalopram offers specific benefits for anxious versus nonanxious depression. The study found that while ziprasidone was equally effective in reducing depressive symptoms across subgroups, it did not provide clinically significant anxiolytic effects in patients with comorbid anxiety, refining expectations for its use in complex mood disorder cases.

• EMD638683: Selective SGK1 Inhibitor for Vascular and Tumor R

  2026-06-08

  EMD638683 is a potent, highly selective SGK1 inhibitor with demonstrated efficacy in modulating endothelial stiffness and tumor growth. It exhibits low off-target activity and is validated for in vitro and in vivo applications, especially in hypertension and cancer research.

414 records 12/28 page Previous Next First page 上5页 1112131415 下5页 Last page